NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) resulting from allegations that Valeant may have issued materially misleading business information to the investing public.
On October 19, 2015, Southern Investigative Reporting Foundation issued a report on Valeant revealing an undisclosed relationship between Valeant and specialty pharmacy Philidor Rx Services. On this news, shares of Valeant fell $13.73 per share or over 7% to close at $163.83 per share on October 19, 2015. On October 21, 2015, Citron Research issued a report on Valeant asserting, among other things, that Valeant and Philidor have created an entire network of phantom captive pharmacies to create fake sales of drugs or to avoid scrutiny from auditors. On this news, shares of Valeant fell sharply during intraday trading on October 21, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Valeant investors. If you purchased shares of Valeant on or before October 21, 2015, please visit the firm’s website at http://rosenlegal.com/cases-757.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.